Metraipolis › archive › dc_ff01a6772993
Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system — Europe PMC PMID:41565210
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41565210
- DOI
- 10.1093/ehjcvp/pvag006
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T08:21:20.640Z
- SHA-256 of the archived text
fdcf375ee272dba5ee16b82a5f3130eea73950d6b43b4356e4ee1f162dc97f48- Stable URL of this page
https://metraipolis.com/documento/dc_ff01a6772993
How to cite
Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system — Europe PMC PMID:41565210 — Europe PMC (en), https://europepmc.org/article/MED/41565210 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ff01a6772993 (Metraipolis archive dc_ff01a6772993, sha256 fdcf375ee272dba5ee16b82a5f3130eea73950d6b43b4356e4ee1f162dc97f48)
BibTeX
@misc{dcff01a6772993,
title = {Cardiac adverse events associated with dual immune checkpoint inhibitors: a pharmacovigilance analysis from the FDA adverse event reporting system — Europe PMC PMID:41565210},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41565210},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ff01a6772993; sha256 fdcf375ee272dba5ee16b82a5f3130eea73950d6b43b4356e4ee1f162dc97f48},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41565210. Agents can read the archived copy with the MCP tool read_document.